Related Experiment Video
Updated: Sep 5, 2025

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
Published on: January 20, 2023
Left ventricular function is related with amphiregulin and fibrosis markers in cirrhotic cardiomyopathy
E Grzebyk1, M Pazgan-Simon2, J Jagas3
1Wroclaw Medical University, Department of Pharmaceutical Biochemistry, Wroclaw, Poland.
Insights
Amphiregulin (ARG) is elevated in cirrhotic cardiomyopathy (CCM), indicating its role in myocardial injury. Monitoring ARG alongside fibrosis and remodeling markers aids in managing heart function in cirrhosis patients.
Area of Science:
- Cardiology
- Hepatology
- Biochemistry
Background:
- Cirrhotic cardiomyopathy (CCM) involves left ventricle (LV) dysfunction, extracellular matrix remodeling, and fibrosis.
- The role of amphiregulin (ARG) in CCM pathogenesis and its association with cardiac remodeling markers is not well understood.
Purpose of the Study:
- To investigate the association between extracellular matrix remodeling markers, ARG, and ventricular remodeling indicators in hepatitis C virus (HCV) patients with cirrhosis.
- To evaluate the relationship between ARG, fibrosis markers, and LV functional parameters in CCM.
Main Methods:
- Echocardiography was used to assess LV diastolic function in 87 HCV patients with cirrhosis, categorizing them into CCM (n=52) and non-CCM (n=35) groups.
- Serum levels of ARG, fibrosis markers (TGF-β1, PICP, PIIINP, TIMP-1), and cardiac remodeling markers (NT-proBNP, hs-TnT) were measured.
- Receiver Operating Characteristic (ROC) analysis was performed to assess the diagnostic performance of ARG and other markers for CCM.
Main Results:
- ARG levels were significantly higher in the CCM group compared to the non-CCM group (P<0.001).
- ARG levels were independently associated with the presence of CCM and correlated significantly with left ventricular diastolic dysfunction (LVDD).
- ARG showed a notable diagnostic performance for CCM (AUROC = 0.709), comparable to hs-TnT (AUROC = 0.753) and superior to PICP (AUROC = 0.662). NT-proBNP was the best diagnostic marker (AUROC = 0.796).
Conclusions:
- Amphiregulin plays an active role in myocardial injury associated with CCM in HCV patients.
- Simultaneous monitoring of serum ARG, fibrosis, and ventricular remodeling markers can aid in managing myocardial function alterations in cirrhotic patients.
Abstract:
The relationship between left ventricle (LV), extracellular matrix remodeling and fibrosis-linked amphiregulin (ARG) in cirrhotic cardiomyopathy (CCM) is unknown. The aim of the study was to investigate the associations between markers of extracellular matrix remodeling and ARG in cirrhosis and their association with indicators of ventricular remodeling and LV functional parameters. In hepatitis C virus (HCV) patients with cirrhosis, who underwent echocardiography, the presence of left ventricular diastolic dysfunction (LVDD) was determined by having gradable diastolic dysfunction in accordance with modified 2020 Cirrhotic Cardiomyopathy Consortium criteria. A total of 87 cirrhotic patients were consecutively analyzed. Based on detailed echocardiographic assessment - 35 HCV patients with cirrhosis had normal left ventricular diastolic function (non-CCM group), whereas 52 patients had LVDD (CCM group). ARG was measured by enzyme-linked immunosorbent assay. The ARG levels were significantly increased in the CCM group compared to the non-CCM group (P<0.001). ARG levels in all HCV patients were independently associated to the presence of CCM, and showed significant correlations with LVDD. The close relationship between ARG levels and the direct serum marker of fibrosis, and selected markers of extracellular matrix (i.e. transforming growth factor-beta1 (TGF-β1), and carboxyterminal propeptide of type I collagen (PICP), amino-terminal propeptide of type III procollagen (PIIINP), tissue inhibitor of matrix proteinase-1 (TIMP-1), respectively), ventricular remodeling (i.e. N-terminal pro B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin-T (hs-TnT)), and LV functional parameters suggest an active role in the myocardial injury. Using ROC analysis, the best marker for the diagnosis of CCM was NT-proBNP with AUROC = 0.796. The area under the curve of ARG (AUROC = 0.709) for predicting CCM was greater than this for PICP (AUROC = 0.662) and similar to this hs-TnT (AUROC = 0.753). The simultaneous monitoring of serum ARG and markers of extracellular matrix and ventricular remodeling can be helpful for the alterations in myocardial function control in HCV patients with cirrhosis.
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Heart Failure II: Pathophysiology
Rheumatic Heart Disease I: Introduction
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Pathophysiology of Heart Failure

